1.260USD+6.78%Mkt Cap: 112.77M USDP/E: —Last update: 2026-06-01
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central n…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap112.77M USD
Enterprise Value69.27M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-23.49M USD
Revenue/Share—
Last Price1.260 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.27
PEG—
EV/EBITDA-1.62
EV/Revenue—
P/S—
P/B3.06
EPS (TTM)-0.23
EPS (Forward)-0.28
52W Range
0.235029% of range3.830
52W High3.830 USD
52W Low0.2350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-68.53%
ROA-48.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.59M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-36.17M USD
Net Debt/EBITDA0.84
Balance Sheet
Debt/Equity0.02
Current Ratio—
Quick Ratio—
Book Value/Sh0.3850 USD
Cash/Share0.4120 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)3.500 USD
Target Range3.000 USD – 4.000 USD
# Analysts4
Ownership
Shares Out.89.50M
Float81.85M
Insiders2.25%
Institutions23.49%
Short Interest
Short Ratio7.5d
Short % Float9.40%
Short % Out.8.67%
Shares Short7.76M
Short (prev mo.)7.32M
Technical
SMA 501.104 (+14.1%)
SMA 2001.444 (-12.7%)
Beta1.81
S&P 52W Chg27.94%
Avg Vol (30d)979.99K
Avg Vol (10d)846.92K
Technical Indicators
RSI (14)49.8
MACD0.0169
MACD Signal0.0238
MACD Hist.-0.0069
BB Upper1.314 USD
BB Middle1.204 USD
BB Lower1.095 USD
BB Width18.20%
ATR (14)0.0907 USD
Vol Ratio (20d)0.76x